https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-16 / Oncotarget 2017 05;8(20):33897-33910
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-16 / Oncotarget 2017 05;8(20):33897-339102017-05-16 00:00:002019-02-15 08:47:54Immunotherapeutic approaches for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-12 / Oncoimmunology 2017;6(7):e1328341
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-12 / Oncoimmunology 2017;6(7):e13283412017-05-12 00:00:002019-02-15 08:45:19Trial watch: Dendritic cell-based anticancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-12 / Nat Rev Neurol 2017 Jun;13(6):363-374
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-12 / Nat Rev Neurol 2017 Jun;13(6):363-3742017-05-12 00:00:002019-02-15 08:47:30Vaccine-based immunotherapeutic approaches to gliomas and beyond
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-12 / J Transl Med 2017 05;15(1):104
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-12 / J Transl Med 2017 05;15(1):1042017-05-12 00:00:002019-02-15 08:47:31A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-03 / Clin. Cancer Res. 2017 Aug;23(16):4556-4568
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-03 / Clin. Cancer Res. 2017 Aug;23(16):4556-45682017-05-03 00:00:002019-02-15 08:45:43Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-27 / Sci Rep 2017 04;7(1):1217
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-27 / Sci Rep 2017 04;7(1):12172017-04-27 00:00:002021-11-15 20:07:45Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-22 / J. Neurooncol. 2017 Jun;133(2):223-235
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-22 / J. Neurooncol. 2017 Jun;133(2):223-2352017-04-22 00:00:002019-02-15 08:47:31Dendritic cell based vaccination strategy: an evolving paradigm
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-20 / Oncoimmunology 2017;6(6):e1319044
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-20 / Oncoimmunology 2017;6(6):e13190442017-04-20 00:00:002019-02-15 08:46:16Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-20 / JCI Insight 2017 Apr;2(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-20 / JCI Insight 2017 Apr;2(8)2017-04-20 00:00:002019-02-15 08:49:48Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-18 / Oncotarget 2017 Apr;8(16):27252-27262
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-18 / Oncotarget 2017 Apr;8(16):27252-272622017-04-18 00:00:002019-02-15 08:39:10Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
